aTYR PHARMA (ATYR) Asset Utilization Ratio (2020 - 2026)

aTYR PHARMA's (ATYR) quarterly Asset Utilization Ratio came in at 0.0 in Q1 2026, up 15.64% on a QoQ basis from 0.0 in Q4 2025.

aTYR PHARMA (ATYR) Asset Utilization Ratio (2020 - 2026) Analysis & Trends

aTYR PHARMA (ATYR) has 6 years of Asset Utilization Ratio data on file, last reported at 0.0 in Q1 2026.

Quarterly Asset Utilization Ratio changed N/A year-over-year to 0.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 0.0 (changed N/A YoY) and the FY2025 annual result came in at 0.0, down 7.37% from the prior year.
Asset Utilization Ratio climbed to 0.0 in Q1 2026, from 0.0 in the prior quarter.
In the past five years, Asset Utilization Ratio ranged from a high of 0.13 in Q4 2022 to a low of 0.0 in Q3 2025.
A 5-year average of 0.03 and a median of 0.01 in 2024 frame the typical range for Asset Utilization Ratio.
The widest YoY moves for Asset Utilization Ratio: up 311.56% in 2023, down 97.78% in 2023.
Tracing ATYR's Asset Utilization Ratio over 5 years: stood at 0.13 in 2022, then slumped by 97.78% to 0.0 in 2023, then retreated by 13.19% to 0.0 in 2024, then fell by 23.69% to 0.0 in 2025, then climbed by 15.64% to 0.0 in 2026.
The last three Asset Utilization Ratio figures came in at 0.0 (Q1 2026), 0.0 (Q4 2025), and 0.0 (Q3 2025), per Business Quant data.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Asset Util. (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn	0.47
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn	0.38
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn	-
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn	0.20
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn	0.69
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn	0.90
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn	0.13
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn	0.54
9	Royalty Pharma	27.27 Bn	26.43 Bn	-	0.13
10	aTYR PHARMA	49.54 Mn	-7.87 Mn	-	-

Download Data